Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lumos Pharma Inc
(NQ:
LUMO
)
1.800
+0.260 (+16.88%)
Streaming Delayed Price
Updated: 3:54 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lumos Pharma Inc
< Previous
1
2
3
4
Next >
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
September 14, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Participation in Investor Conferences in September
September 07, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
What 7 Analyst Ratings Have To Say About Lumos Pharma
September 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Lumos Pharma
August 15, 2023
Via
Benzinga
Lumos Pharma: Q1 Earnings Insights
May 03, 2023
Via
Benzinga
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
A Preview Of Lumos Pharma's Earnings
February 28, 2023
Via
Benzinga
Lumos Pharma Earnings Perspective: Return On Capital Employed
December 26, 2022
Via
Benzinga
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
August 22, 2023
Virtual Webinar to be held September 5, 2023, at 11:00 AM Eastern Time
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
August 09, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
July 26, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
July 12, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
June 29, 2023
Via
Benzinga
Lumos Pharma Announces Departure of Chief Medical Officer
June 28, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
June 21, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
May 31, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
May 25, 2023
KOL Webinar to be held June 21, 2023 at 11:00 AM Eastern Time
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in World Orphan Drug Congress USA
May 22, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)
May 08, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
May 03, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
April 27, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
April 19, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023
March 09, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
March 05, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
March 01, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
February 28, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023
February 15, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
January 03, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
December 12, 2022
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lowe's To Rally Around 19%? Here Are 10 Other Price Target Changes For Thursday
December 08, 2022
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.